JMD ASIP MEMBERSHIP
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Dandachi, N.
Right arrow Articles by Bauernhofer, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Dandachi, N.
Right arrow Articles by Bauernhofer, T.
JMD 2005, Vol. 7, No. 5
Copyright © 2005 American Society for Investigative Pathology & Association for Molecular Pathology

Critical Evaluation of Real-Time Reverse Transcriptase-Polymerase Chain Reaction for the Quantitative Detection of Cytokeratin 20 mRNA in Colorectal Cancer Patients

Nadia Dandachi*, Marija Balic*, Stefanie Stanzer*, Michael Halm*, Margit Resel*, Thomas Anton Hinterleitner{dagger}, Hellmut Samonigg* and Thomas Bauernhofer*

From the Divisions of Clinical Oncology * and Gastroenterology and Hepatology, {dagger} Department of Internal Medicine, Medical University Graz, Austria

We evaluated the usefulness of cytokeratin 20 (CK20) mRNA expression in the quantitative detection of circulating tumor cells in the blood of patients with colorectal cancer (CRC). Blood samples from healthy volunteers (HVs; n = 37), patients with localized (n = 42) and metastatic colorectal cancer (n = 40), and patients with chronic inflammatory bowel disease (CID; n = 15) were examined. After immunomagnetic enrichment using microbeads against human epithelial antigen, total RNA was extracted, reverse transcribed, and analyzed by real-time reverse transcriptase-polymerase chain reaction using the LightCycler instrument. CK20 expression in peripheral blood was found in 46 of 82 (56%) patients with CRC, 8 of 37 (22%) HVs, and 9 of 15 (60%) patients with CID. Levels of CK20 mRNA were significantly higher in blood samples from CRC patients (median 681) than in blood samples from HVs (median 0) (P = 0.001), whereas no difference could be detected between patients with CRC and CID. Although the present technique could not distinguish CRC from CID, the method warrants further efforts to improve sample preparation and tumor cell enrichment, which may render real-time CK20 reverse transcriptase-polymerase chain reaction a feasible technique in identifying circulating tumor cells in peripheral blood of cancer patients.




This article has been cited by other articles:


Home page
 Jpn J Clin OncolHome page
C. Shen, L. Hu, L. Xia, and Y. Li
Quantitative Real-time RT-PCR Detection for Survivin, CK20 and CEA in Peripheral Blood of Colorectal Cancer Patients
Jpn. J. Clin. Oncol., November 1, 2008; 38(11): 770 - 776.
[Abstract] [Full Text] [PDF]

Home page
 INT J SURG PATHOLHome page
C. S.-C. Wong, M.-T. Cheung, B. B.-Y. Ma, E. Pun Hui, A. C.-L. Chan, C.-K. Chan, K.-C. Lee, W. Cheuk, M. Y.-Y. Lam, M. C.-K. Wong, et al.
Isolated Tumor Cells and Circulating CK20 mRNA in pN0 Colorectal Cancer Patients
International Journal of Surgical Pathology, April 1, 2008; 16(2): 119 - 126.
[Abstract] [PDF]

Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
S. Hundt, U. Haug, and H. Brenner
Blood Markers for Early Detection of Colorectal Cancer: A Systematic Review
Cancer Epidemiol. Biomarkers Prev., October 1, 2007; 16(10): 1935 - 1953.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2005 by the American Society for Investigative Pathology and the Association for Molecular Pathology.